Oncopeptides AB

Oncopeptides AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO®(melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. The first one is expected to enter into clinical development in 2021.Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Oncopeptides AB Interim Report July - September 2017

Wed, Nov 15, 2017 08:00 CET

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the third quarter 2017 report. “The data from our study, O-12-M1, provides us with an increased degree of comfort regarding a positive clinical outcome in our pivotal study OCEAN” SUMMARY OF Q3 July 1st – September 30th 2017 Significant events after the period · Net sales amounted to 0.0 (0.0) July 1st to September 30th 2017MSEK · On November 1st, we announced that · Loss for the period was 51.6 we will present results from two(loss: 24.7) MSEK

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Oncopeptides AB Interim Report July - September 2017

Subscribe

Media